Found: 12
Select item for more details and to access through your institution.
FDG PET/CT and Dosimetric Studies of <sup>177</sup>Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma-Are We Hitting the Target?
- Published in:
- 2022
- By:
- Publication type:
- journal article
Correlations between [ 68 Ga]Ga-DOTA-TOC Uptake and Absorbed Dose from [ 177 Lu]Lu-DOTA-TATE.
- Published in:
- Cancers, 2023, v. 15, n. 4, p. 1134, doi. 10.3390/cancers15041134
- By:
- Publication type:
- Article
Radionuclides for Targeted Therapy: Physical Properties.
- Published in:
- Molecules, 2022, v. 27, n. 17, p. 5429, doi. 10.3390/molecules27175429
- By:
- Publication type:
- Article
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [<sup>177</sup>Lu]Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 8, p. 1, doi. 10.2967/jnumed.123.266843
- By:
- Publication type:
- Article
SPECT/CT Image-Derived Absorbed Dose to Red Marrow Correlates with Hematologic Toxicity in Patients Treated with [<sup>177</sup>Lu]Lu-DOTATATE.
- Published in:
- Journal of Nuclear Medicine, 2024, v. 65, n. 5, p. 753, doi. 10.2967/jnumed.123.266843
- By:
- Publication type:
- Article
Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody-Radionuclide Conjugate <sup>177</sup>Lu-Lilotomab Satetraxetan.
- Published in:
- Journal of Nuclear Medicine, 2018, v. 59, n. 4, p. 704, doi. 10.2967/jnumed.117.195347
- By:
- Publication type:
- Article
Red Marrow–Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with <sup>177</sup>Lu-Lilotomab Satetraxetan, a Novel Anti-CD37 Antibody–Radionuclide Conjugate.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 1, p. 55, doi. 10.2967/jnumed.116.180471
- By:
- Publication type:
- Article
Tumor-Absorbed Dose for Non-Hodgkin Lymphoma Patients Treated with the Anti-CD37 Antibody Radionuclide Conjugate <sup>177</sup>Lu-Lilotomab Satetraxetan.
- Published in:
- Journal of Nuclear Medicine, 2017, v. 58, n. 1, p. 48, doi. 10.2967/jnumed.116.173922
- By:
- Publication type:
- Article
Myelosuppression in patients treated with <sup>177</sup>Lutetium-lilotomab satetraxetan can be predicted with absorbed dose to the red marrow as the only variable.
- Published in:
- Acta Oncologica, 2021, v. 60, n. 11, p. 1481, doi. 10.1080/0284186X.2021.1959635
- By:
- Publication type:
- Article
EANM guidance document: dosimetry for first-in-human studies and early phase clinical trials.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2024, v. 51, n. 5, p. 1268, doi. 10.1007/s00259-024-06640-x
- By:
- Publication type:
- Article
FDG PET/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of 177Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2021, v. 48, n. 6, p. 1902, doi. 10.1007/s00259-020-05098-x
- By:
- Publication type:
- Article
Pre-dosing with lilotomab prior to therapy with <sup>177</sup>Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2018, v. 45, n. 7, p. 1233, doi. 10.1007/s00259-018-3964-9
- By:
- Publication type:
- Article